α-Conotoxin TxID and [S9K]TxID, α3β4 nAChR Antagonists, Attenuate Expression and Reinstatement of Nicotine-Induced Conditioned Place Preference in Mice.
Xiaodan LiShen YouJian XiongYamin QiaoJinpeng YuDongting ZhangsunSu-Lan LuoPublished in: Marine drugs (2020)
Tobacco smoking has become a prominent health problem faced around the world. The α3β4 nicotinic acetylcholine receptor (nAChR) is strongly associated with nicotine reward and withdrawal symptom. α-Conotoxin TxID, cloned from Conus textile, is a strong α3β4 nAChR antagonist, which has weak inhibition activity of α6/α3β4 nAChR. Meanwhile, its analogue [S9K]TxID only inhibits α3β4 nAChR (IC50 = 6.9 nM), and has no inhibitory activity to other nAChRs. The present experiment investigates the effect of α3β4 nAChR antagonists (TxID and [S9K]TxID) on the expression and reinstatement of nicotine-induced conditioned place preference (CPP) and explores the behaviors of acute nicotine in mice. The animal experimental results showed that TxID and [S9K] TxID could inhibit the expression and reinstatement of CPP, respectively. Moreover, both had no effect in acute nicotine experiment and the locomotor activity in mice. Therefore, these findings reveal that the α3β4 nAChR may be a potential target for anti-nicotine addiction treatment. [S9K]TxID, α3β4 nAChR antagonist, exhibit a superior effect for anti-nicotine addiction, which is promising to develop a novel smoking cessation drug.
Keyphrases
- smoking cessation
- replacement therapy
- poor prognosis
- drug induced
- liver failure
- binding protein
- healthcare
- high fat diet induced
- public health
- diabetic rats
- respiratory failure
- oxidative stress
- high glucose
- type diabetes
- photodynamic therapy
- genome wide
- hepatitis b virus
- dna methylation
- metabolic syndrome
- single cell
- intensive care unit
- gene expression
- extracorporeal membrane oxygenation
- wastewater treatment
- health information
- endothelial cells
- wild type